bufalin has been researched along with Cardiovascular Stroke in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, R; Lv, Y; Wei, X; Xu, Y; Yang, C; Zou, S | 1 |
| Batkai, S; Einzinger, P; Gyöngyösi, M; Hasimbegovic, E; Kastner, N; Lukovic, D; Mester-Tonczar, J; Spannbauer, A; Thum, T; Traxler, D; Winkler, J; Zlabinger, K | 1 |
2 other study(ies) available for bufalin and Cardiovascular Stroke
| Article | Year |
|---|---|
Bufalin reduces myocardial infarction-induced myocardial fibrosis and improves cardiac function by inhibiting the NLRP3/IL-1β signalling pathway.
Topics: Animals; Disease Models, Animal; Fibrosis; Inflammasomes; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; NLR Family, Pyrin Domain-Containing 3 Protein; Stroke Volume; Sulfonamides; Ventricular Function, Left | 2023 |
Association between Circular RNA CDR1as and Post-Infarction Cardiac Function in Pig Ischemic Heart Failure: Influence of the Anti-Fibrotic Natural Compounds Bufalin and Lycorine.
Topics: Amaryllidaceae Alkaloids; Animals; Bufanolides; Disease Models, Animal; Humans; Injections, Subcutaneous; Male; Myocardial Infarction; Phenanthridines; RNA, Circular; RNA, Long Noncoding; Stroke Volume; Swine; Treatment Outcome; Up-Regulation; Ventricular Remodeling | 2020 |